
OMDA Stock Forecast & Price Target
OMDA Analyst Ratings
Bulls say
Omada Health Inc reported an impressive 49.5% year-over-year revenue growth, attributed to a significantly higher member base, which reached 831,000 by the end of 3Q25, exceeding previous estimates. Gross margins also benefited from a more efficient care team and an improved program mix, expanding to 68.2%, surpassing expectations. The company's strong performance and strategic positioning in the cardiometabolic health sector are expected to propel growth rates exceeding 50% in FY25 while simultaneously enhancing EBITDA margins into positive territory.
Bears say
The analysis reveals a negative outlook for Omada Health's stock, primarily due to concerns regarding a potentially short-lived GLP-1-driven growth cycle, which is projected to result in a slowdown to approximately 20% growth. Additionally, the ramp in adjusted EBITDA is expected to decelerate post-2025 as the company invests in its new GLP-1 care track, raising doubts about the sustainability of high margins in the long term. Furthermore, increased competition and price reductions in the GLP-1 space could diminish profitability, necessitating enhanced management solutions for delivery optimization to address rising demand for weight loss offerings.
This aggregate rating is based on analysts' research of Omada Health Inc and is not a guaranteed prediction by Public.com or investment advice.
OMDA Analyst Forecast & Price Prediction
Start investing in OMDA
Order type
Buy in
Order amount
Est. shares
0 shares